Highflying Biotech Stock Sets Up After 96% Pop; Annual Profit In Sight As Key Drug Sales Double

Core Insights - Alnylam Pharmaceuticals has experienced a significant stock increase of approximately 96% in 2025, driven by the growing uptake of its primary drug, Amvuttra [1][4] - Despite a recent decline from its all-time high of 495.55 following strong third-quarter results, the stock remains a notable performer in the biotech sector [1][4] - The company has received an upgrade in its relative strength rating, indicating improved market performance [4] Company Performance - Alnylam Pharmaceuticals' stock has nearly doubled in value during 2025, showcasing strong market interest and investor confidence [4] - The stock faced a setback due to earnings reports, but overall performance remains robust [4] Market Context - The broader stock market has shown volatility, with various companies, including Alnylam, being closely monitored for potential investment opportunities [4] - Other notable companies in focus alongside Alnylam include CrowdStrike and Oracle, indicating a competitive landscape in the tech and biotech sectors [4]